Investment

Features

Fees Safety

Academy

Pluang+

Home/News Feed/Neurocrine shares jump 27% this year on strong sales and pipeline growth.

NBIX

$174.37

-$2.74 -1.55%

Neurocrine shares jump 27% this year on strong sales and pipeline growth.

Company Fundamentals

10 Jul 2026

FXEmpire

View Source

Bullish

Neurocrine Biosciences saw its shares rise 27% in 2026, driven by over $800 million in Q1 product sales and a 44% growth in its key drug INGREZZA. The company reported around $200 million in net income and has a robust pipeline with 12 programs currently and five more planned this year. Institutional investors have shown strong buying interest, pushing the stock higher since May. With solid sales and earnings growth, Neurocrine is positioned as a promising stock for diversified portfolios.

More News (NBIX)

Neurocrine Biosciences schedules Q2 2026 earnings call for July 30

Neurocrine Biosciences announced its Q2 2026 financial results conference call and webcast will be held on July 30, 2026, at 1:30 p.m. Pacific Time. The company will release its earnings report earlier that day at 1:00 p.m. PT. Investors can access t...

Company Fundamentals

Neutral

4 days ago